US Patent 8,524,733: Claim Scope, Deutetrabenazine Patent Landscape, and Generic Entry Risk
US Patent 8,524,733 covers a deuterium-enriched tetrabenazine compound and pharmaceutical compositions containing it. The patent is an active-ingredient patent rather than a conventional formulation or method-of-use patent. Its commercial relevance is tied to deutetrabenazine, the active ingredient in Teva’s Austedo and Austedo XR products, which are approved for chorea associated with Huntington’s disease and tardive dyskinesia.[1]
The core protection requires deuterium at every position identified as “D” in the patented structure, with at least about 90% enrichment under claim 1 and at least about 98% enrichment under claim 2. Claim 3 extends protection to pharmaceutical compositions containing the claimed compound.
What does US Patent 8,524,733 protect?
The patent protects a specific deuterated tetrabenazine compound, its salts, and pharmaceutical compositions containing that compound.
| Claim |
Protected subject matter |
Principal limitation |
| 1 |
Deuterated compound or salt |
Each designated D position must have at least about 90% deuterium enrichment |
| 2 |
Compound of claim 1 |
Each designated D position must have at least about 98% deuterium enrichment |
| 3 |
Pharmaceutical composition |
Must contain the claim 1 compound and a pharmaceutically acceptable carrier |
The structure shown in the patent is essential to claim interpretation. The claim is not a broad monopoly over all deuterated VMAT2 inhibitors. It is directed to the particular tetrabenazine-derived molecular configuration shown in the claim.
The patent’s commercial significance comes from replacing selected hydrogen atoms in tetrabenazine with deuterium. Deuterium can alter metabolic cleavage rates and pharmacokinetic exposure. Deutetrabenazine was developed to provide a longer effective exposure profile than tetrabenazine, potentially supporting less frequent dosing and different tolerability characteristics.[2]
How does the deuterium-enrichment limitation affect infringement?
The enrichment language is a central limitation.
A product generally must satisfy both requirements:
- It must have the claimed molecular structure.
- Every position marked D must meet the specified enrichment threshold.
Claim 1 establishes a threshold of approximately 90% deuterium enrichment at each designated position. Claim 2 narrows that threshold to approximately 98%. A product with the correct structure but materially lower enrichment could fall outside the literal scope of the claims.
The wording “each position represented as D” is important. The claim does not appear to require only a total deuterium content. It requires the enrichment threshold at each specified isotopic position. Analytical testing would therefore need to evaluate positional isotopic composition, not simply the aggregate percentage of deuterium in the batch.
The claim also covers salts. A pharmaceutically acceptable salt may remain within claim 1 if the underlying deuterated molecular structure and enrichment requirements are satisfied.
What compounds are outside the literal scope of US 8,524,733?
The patent does not, based on the supplied claims, expressly cover:
- Unmodified tetrabenazine lacking the claimed deuterium substitutions.
- Deuterated compounds with a different substitution pattern.
- Deuterated analogues having a different core structure.
- Compounds below the claim 1 enrichment threshold.
- Deuterated metabolites that do not have the claimed structure.
- Formulations that do not contain the claimed compound.
- Manufacturing processes, unless another claim in the patent family covers them.
- Methods of treating Huntington’s disease or tardive dyskinesia, unless separately claimed in related patents.
This distinction matters for generic design-around analysis. A competitor could attempt to use a different isotopologue, a different deuterium placement, or a chemically distinct VMAT2 inhibitor. Such strategies would require separate analysis under the doctrine of equivalents and under related patents in the same family.
What is the relationship between US 8,524,733 and Austedo?
Austedo contains deutetrabenazine, a deuterated tetrabenazine derivative. The FDA approved Austedo tablets in April 2017 for chorea associated with Huntington’s disease and tardive dyskinesia.[1] FDA later approved Austedo XR, an extended-release formulation, for the same general therapeutic market.[3]
The relationship is commercially direct:
| Product |
Active ingredient |
Regulatory route |
Commercial relevance |
| Austedo tablets |
Deutetrabenazine |
NDA 208082 |
Original twice-daily product |
| Austedo XR |
Deutetrabenazine |
Supplemental NDA |
Extended-release product |
| Xenazine |
Tetrabenazine |
NDA 021894 |
Predecessor VMAT2 inhibitor |
| Generic tetrabenazine |
Tetrabenazine |
ANDA |
Does not necessarily practice deuterated-compound claims |
Patent 8,524,733 is principally an active-ingredient patent. It therefore has greater relevance to products containing the covered deuterated compound than to ordinary tetrabenazine products.
When does US Patent 8,524,733 expire?
The patent issued on September 3, 2013. Its effective expiration depends on the earliest applicable nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any patent-term extension.
Public patent and regulatory databases generally associate the patent with an expiration date in or around 2030. The precise enforceable date should be taken from the USPTO patent file and current FDA Orange Book listing, rather than calculated solely from the grant date.[4][5]
The patent term is separate from FDA regulatory exclusivity. Austedo’s five-year new chemical entity exclusivity expired in 2022, based on the 2017 approval date. Loss of NCE exclusivity did not eliminate unexpired patent rights.
Exclusivity timeline
| Event |
Date |
| Patent issued |
September 3, 2013 |
| Austedo FDA approval |
April 3, 2017 |
| Five-year NCE exclusivity |
Through approximately April 3, 2022 |
| Expected patent protection associated with US 8,524,733 |
Approximately 2030, subject to official term calculation |
| Potential generic entry |
Controlled by patent certifications, litigation, settlements, and any later Orange Book patents |
What is the Orange Book status of US 8,524,733?
The patent has been associated with the Austedo patent estate and has been cited in connection with the deuterated active ingredient. Orange Book listing status is product-specific. A patent may be listed for one NDA or dosage form and not for another.
Orange Book relevance depends on whether the patent claims:
- The active ingredient;
- An approved method of use;
- A drug substance or drug product;
- A specific extended-release formulation; or
- A manufacturing process that falls within FDA listing rules.
For an ANDA applicant, an Orange Book-listed patent can trigger a Paragraph III certification, a Paragraph IV certification, or another certification depending on the patent’s listed expiration and claim scope. A Paragraph IV notice can lead to a 45-day period for the NDA holder or patent owner to file an infringement action, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[6]
How strong is the patent estate for deutetrabenazine?
US 8,524,733 is commercially important but should be evaluated as one component of a layered patent estate.
Active-ingredient protection
The patent’s strongest feature is that it claims the deuterated compound itself. An active-ingredient claim can block a competing product regardless of whether the competitor uses a different tablet excipient or manufacturing process, provided the competitor makes, uses, or sells the claimed compound.
Isotopic-position limitation
The principal vulnerability is the narrow structural and isotopic definition. A challenger may argue that its product has a different isotopic distribution, a different stereochemical form, or a different molecular structure.
Composition protection
Claim 3 is narrower than the compound claim because it requires a pharmaceutical composition containing the claimed compound. It can reach tablets, capsules, solutions, or other dosage forms if the composition includes the claimed compound and a pharmaceutically acceptable carrier.
The claim does not, on its face, require a particular dosage strength, release profile, excipient, particle size, or manufacturing process.
Lack of express method claims in the supplied claims
The supplied claim set does not include a treatment method. It therefore does not independently establish protection for a particular indication, dosing schedule, titration regimen, or patient population. Related patents may provide that protection.
What formulation patents protect Austedo XR?
The supplied claims do not specifically claim an extended-release formulation. Claim 3 covers a composition containing the deuterated compound, but it does not expressly require:
- Extended release;
- A polymer matrix;
- A coated multiparticulate;
- A specified dissolution profile;
- A once-daily dosage form;
- A particular excipient system; or
- A defined pharmacokinetic profile.
Austedo XR may therefore depend on separate formulation, dosage-form, or method-of-use patents. Those patents must be reviewed independently because infringement of US 8,524,733 cannot be assumed merely because a product is extended release.
Which companies could challenge the patent?
Potential ANDA challengers include generic pharmaceutical companies developing deutetrabenazine tablets or other immediate-release products. A generic applicant could challenge the patent through a Paragraph IV certification, argue non-infringement based on isotopic composition or structure, or seek approval after patent expiration through a Paragraph III certification.
The principal risk categories are:
| Challenger strategy |
Impact on patent |
| Paragraph III certification |
Delays approval until listed patent expiry |
| Paragraph IV certification |
Creates litigation risk and may accelerate a judicial validity decision |
| Different isotopic distribution |
May avoid literal infringement |
| Different salt or solid form |
May avoid or complicate infringement depending on claim construction |
| 505(b)(2) application |
More relevant where the applicant relies partly on existing clinical data but uses a materially different product |
| Non-deuterated tetrabenazine ANDA |
Generally does not practice the deuterated-compound claims |
No biosimilar pathway applies. Deutetrabenazine is a chemically synthesized small molecule, not a biologic. Competitive entry would normally proceed through an ANDA or, in some cases, a 505(b)(2) application rather than through the Biologics Price Competition and Innovation Act pathway.
What litigation and settlement risks affect generic launch?
A Paragraph IV notice directed to US 8,524,733 could produce patent litigation against the NDA holder or patent owner. The central litigation issues would likely include:
- Claim construction of the depicted molecular structure;
- The identity and location of the designated deuterium atoms;
- Whether the accused product meets the 90% or 98% enrichment threshold;
- Infringement by salts or solid forms;
- Written description and enablement;
- Obviousness over tetrabenazine and deuterated analogues;
- Anticipation by prior-art isotopologues;
- The scope of related Austedo patents;
- Whether a settlement permits an earlier launch date.
A settlement could authorize an “at-risk” or licensed launch before nominal patent expiry, or could provide a deferred entry date. The commercial value of a settlement depends on remaining Austedo revenue, the number of approved or pending ANDAs, and the breadth of the patent family.
What revenue exposure does the patent create?
The patent’s revenue exposure is concentrated in products containing the covered deuterated active ingredient. It is less relevant to tetrabenazine products that do not contain the patented isotopologue.
Key commercial factors include:
- Austedo prescription growth in tardive dyskinesia;
- Huntington’s disease market size;
- Conversion from Austedo tablets to Austedo XR;
- Payer coverage and net pricing;
- The number of generic entrants;
- Whether generic products launch immediately after patent expiry or through an earlier settlement;
- Whether separate formulation patents delay XR competition.
Teva acquired Auspex Pharmaceuticals in 2015 in a transaction valued at approximately $3.5 billion, primarily to obtain Auspex’s deutetrabenazine program and related assets.[7] That transaction reflects the strategic value assigned to the deuterated active ingredient before FDA approval.
How does US 8,524,733 compare with ordinary tetrabenazine patents?
| Issue |
US 8,524,733 |
Tetrabenazine patent estate |
| Active ingredient |
Deuterated tetrabenazine derivative |
Non-deuterated tetrabenazine |
| Product relevance |
Austedo and related deutetrabenazine products |
Xenazine and generic tetrabenazine |
| Regulatory pathway |
Deutetrabenazine NDA products |
Tetrabenazine NDA and ANDA products |
| Main technical distinction |
Positional deuterium substitution and enrichment |
Original tetrabenazine structure |
| Biosimilar exposure |
None |
None |
| Generic risk |
Requires a product practicing the deuterated structure or related claims |
Separate generic pathway |
| Commercial protection |
Directly tied to Austedo active ingredient |
Does not automatically block Austedo generics |
Key Takeaways
- US Patent 8,524,733 claims a specific deuterated tetrabenazine compound, its salts, and compositions containing it.
- Claim 1 requires at least about 90% deuterium enrichment at every designated D position.
- Claim 2 raises the enrichment threshold to at least about 98%.
- Claim 3 covers pharmaceutical compositions containing the claim 1 compound.
- The patent is an active-ingredient patent, not an express extended-release or method-of-use claim based on the supplied claims.
- Austedo’s 2017 FDA approval created regulatory exclusivity that ended separately from the patent term.
- The patent is generally associated with protection extending to approximately 2030, subject to the official USPTO term calculation and Orange Book record.
- Generic entry would most likely occur through an ANDA and could involve a Paragraph IV challenge.
- No biosimilar pathway applies because deutetrabenazine is a small-molecule drug.
- The commercial risk depends on related active-ingredient, formulation, method-of-use, and manufacturing patents in the broader Austedo estate.
FAQs About US Patent 8,524,733
Does US 8,524,733 cover tetrabenazine?
No. The supplied claims require the specific deuterated structure shown in the patent. Ordinary tetrabenazine without the claimed deuterium substitutions would not satisfy the literal compound limitation.
Can a generic avoid US 8,524,733 by using a different salt?
Possibly, but not automatically. Claim 1 expressly includes “a salt thereof.” A different salt may still infringe if the underlying deuterated compound and enrichment requirements are met.
Does the patent cover Austedo XR?
It may cover the active ingredient in Austedo XR, but the supplied claims do not expressly require extended release. Separate formulation or dosage-form patents may be more important for Austedo XR launch timing.
Is a Paragraph IV challenge required for a generic deutetrabenazine product?
Not necessarily. An ANDA applicant could use a Paragraph III certification and wait for patent expiration. A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed.
Can a competitor develop a different deuterated VMAT2 inhibitor?
Yes, subject to separate patent rights. US 8,524,733 is directed to the claimed tetrabenazine-derived structure and does not, based on the supplied claims, cover every deuterated VMAT2 inhibitor.
References
- U.S. Food and Drug Administration. (2017). FDA approves first drug to treat tardive dyskinesia.
- FDA Center for Drug Evaluation and Research. (2017). Austedo prescribing information.
- U.S. Food and Drug Administration. (2023). Austedo XR approval information and prescribing information.
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,524,733, Deuterated tetrabenazine.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- Hatch-Waxman Amendments, 21 U.S.C. § 355(j).
- Teva Pharmaceutical Industries Ltd. (2015). Teva to acquire Auspex Pharmaceuticals.
